Acura Pharmaceuticals Inc. (NASDAQ:ACUR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Halsey Drug Company, Inc. is engaged in the manufacture, sale and distribution of generic drugs. A generic drug is the chemical and therapeutic equivalent of a brand-name drug for which patent protection has expired. The company sells its generic drug products under its Halsey label and under private-label arrangements with drugstore chains and drug wholesalers. “

A number of other brokerages have also recently weighed in on ACUR. FBR & Co reaffirmed a “buy” rating and set a $10.00 price target on shares of Acura Pharmaceuticals in a research report on Thursday, August 11th. Roth Capital set a $6.00 price objective on shares of Acura Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, October 18th.

Acura Pharmaceuticals (NASDAQ:ACUR) opened at 1.03 on Tuesday. The stock’s market cap is $12.19 million. The company’s 50 day moving average price is $1.22 and its 200-day moving average price is $1.81. Acura Pharmaceuticals has a 12-month low of $0.86 and a 12-month high of $3.52.

Acura Pharmaceuticals (NASDAQ:ACUR) last announced its quarterly earnings results on Monday, November 14th. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.08. Acura Pharmaceuticals had a negative net margin of 291.24% and a negative return on equity of 206.68%. On average, analysts forecast that Acura Pharmaceuticals will post ($1.05) EPS for the current year.

About Acura Pharmaceuticals

Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.

5 Day Chart for NASDAQ:ACUR

Receive News & Stock Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.